Quantum-Si (NASDAQ:QSI) Releases Earnings Results, Beats Expectations By $0.02 EPS
by Teresa Graham · The Cerbat GemQuantum-Si (NASDAQ:QSI – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02, FiscalAI reports. Quantum-Si had a negative net margin of 5,605.88% and a negative return on equity of 46.05%. The business had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.30 million.
Here are the key takeaways from Quantum-Si’s conference call:
- Proteus reached a major technical milestone — Quantum-Si completed sequencing on fully integrated Proteus instruments detecting 17 amino acids and expects 18 by end-2026 with detection of all 20 during 2026 and a full sequencing kit in 2027, which management frames as a significant de‑risking versus Platinum.
- Early customer evaluations and commercial preparation look constructive — a prototype customer reported ~2x average read length and more amino acids detected versus Platinum, the company is running Proteus Roadshows and plans broader sample evaluations to build a buyer funnel, and has positioned Proteus at $425,000 versus >$1M for comparable high-end mass spec alternatives.
- Financial position supports the plan — Quantum‑Si had $190.4M in cash and investments at 3/31/26 and guides 2026 adjusted OpEx ≤ $98M and cash use ≤ $93M, projecting runway into Q2 2028 to fund Proteus completion and launch readiness.
- Near‑term revenue will remain limited — Q1 revenue was only $258k and the company reiterates 2026 revenue around ≈ $1M, describing 2026 as a transition year with modest capital sales as customers delay purchases pending Proteus availability.
Quantum-Si Stock Performance
Shares of NASDAQ:QSI traded down $0.07 on Friday, hitting $0.91. 13,112,028 shares of the company were exchanged, compared to its average volume of 6,228,345. The company’s 50 day moving average price is $0.90 and its two-hundred day moving average price is $1.20. The firm has a market capitalization of $196.16 million, a price-to-earnings ratio of -1.78 and a beta of 3.15. Quantum-Si has a one year low of $0.69 and a one year high of $3.10.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on QSI. Canaccord Genuity Group cut their price objective on Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a research report on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Quantum-Si in a research report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $3.25.
Read Our Latest Research Report on Quantum-Si
Insider Activity at Quantum-Si
In related news, Director Paula Dowdy bought 109,890 shares of Quantum-Si stock in a transaction that occurred on Thursday, March 5th. The stock was acquired at an average price of $0.95 per share, for a total transaction of $104,395.50. Following the completion of the purchase, the director owned 269,107 shares in the company, valued at approximately $255,651.65. This represents a 69.02% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jeffrey Alan Hawkins sold 83,712 shares of the stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $1.01, for a total transaction of $84,549.12. Following the completion of the sale, the chief executive officer owned 3,776,135 shares of the company’s stock, valued at approximately $3,813,896.35. The trade was a 2.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 212,904 shares of company stock worth $205,021 in the last three months. Corporate insiders own 22.04% of the company’s stock.
Hedge Funds Weigh In On Quantum-Si
Several large investors have recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC raised its stake in shares of Quantum-Si by 33.1% in the 3rd quarter. Bridgeway Capital Management LLC now owns 261,100 shares of the company’s stock valued at $368,000 after buying an additional 65,000 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of Quantum-Si in the 4th quarter valued at $305,000. Barclays PLC raised its stake in shares of Quantum-Si by 21.8% in the 4th quarter. Barclays PLC now owns 269,415 shares of the company’s stock valued at $296,000 after buying an additional 48,205 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in shares of Quantum-Si by 34.2% in the 4th quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 253,895 shares of the company’s stock valued at $279,000 after buying an additional 64,721 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Quantum-Si in the 4th quarter valued at $262,000. Institutional investors and hedge funds own 39.90% of the company’s stock.
About Quantum-Si
Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.
Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.